Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;21(4):585-91.
doi: 10.3201/eid2014.140759.

Population structure and antimicrobial resistance of invasive serotype IV group B Streptococcus, Toronto, Ontario, Canada

Population structure and antimicrobial resistance of invasive serotype IV group B Streptococcus, Toronto, Ontario, Canada

Sarah Teatero et al. Emerg Infect Dis. 2015 Apr.

Erratum in

  • Emerg Infect Dis. 2015 Aug;21(8):1489

Abstract

We recently showed that 37/600 (6.2%) invasive infections with group B Streptococcus (GBS) in Toronto, Ontario, Canada, were caused by serotype IV strains. We report a relatively high level of genetic diversity in 37 invasive strains of this emerging GBS serotype. Multilocus sequence typing identified 6 sequence types (STs) that belonged to 3 clonal complexes. Most isolates were ST-459 (19/37, 51%) and ST-452 (11/37, 30%), but we also identified ST-291, ST-3, ST-196, and a novel ST-682. We detected further diversity by performing whole-genome single-nucleotide polymorphism analysis and found evidence of recombination events contributing to variation in some serotype IV GBS strains. We also evaluated antimicrobial drug resistance and found that ST-459 strains were resistant to clindamycin and erythromycin, whereas strains of other STs were, for the most part, susceptible to these antimicrobial drugs.

Keywords: Canada; Streptococcus agalactiae; Toronto; antimicrobial resistance; bacteria; bacterial infection; group B Streptococcus; invasive bacterial disease; multilocus sequence typing; population structure; serotype IV; streptococci; whole-genome sequencing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Inferred genetic relationships of invasive serotype IV group B Streptococcus (GBS), Toronto, Ontario, Canada. A) Neighbor-joining phylogenetic tree constructed by using the concatenated sequences of the 7 gene loci (sdhA, adhP, tkt, glcK, atr, pheS, and glnA) used in the multilocus sequence typing (MLST) scheme for GBS. Each circle represents a single MLST sequence type (ST); circle colors differentiate the 6 STs found among strains in our collection and their sizes are proportional to the number of isolates. B) Neighbor-joining phylogenetic analysis based on concatenated sequences of 316 nonredundant single-nucleotide polymorphism (SNP) loci identified by whole-genome sequencing relative to the core genome ST-452 reference strain NGBS572, which shows further diversity within ST-452. C) Diversity within ST-459 serotype IV GBS shown by neighbor-joining phylogenetic analysis based on concatenated sequences of 526 nonredundant SNP loci relative to the core genome of ST-459 reference strain NGBS061. Scale bars indicate nucleotide substitutions per site.
Figure 2
Figure 2
Susceptibility to erythromycin, clindamycin, and tetracycline among serotype IV group B Streptococcus and sequence types (STs), Toronto, Ontario, Canada. All ST-459 strains and 1 ST-291 strain were resistant to erythromycin; we detected ermTR and ermT genes in all erythromycin-resistant strains (Technical Appendix). Resistance to clindamycin was observed only among ST-459 strains. Resistance to tetracycline was common among all STs except ST-452 and correlated with presence of the tetM gene in isolates (Technical Appendix). Scale bars indicate nucleotide substitutions per site.

Similar articles

Cited by

References

    1. Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis. 2001;33:556–61. 10.1086/322696 - DOI - PubMed
    1. Phares CR, Lynfield R, Farley MM, Mohle-Boetani J, Harrison LH, Petit S, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999–2005. JAMA. 2008;299:2056–65. 10.1001/jama.299.17.2056 - DOI - PubMed
    1. Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, Gershman K, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect Dis. 2009;49:85–92. 10.1086/599369 - DOI - PubMed
    1. Centers for Disease Control and Prevention. Active bacterial core surveillance report, Emerging Infections Program Network, group B Streptococcus, 2011. 2012 [cited 2014 Mar 26]. http://www.cdc.gov/abcs/reports-findings/survreports/gbs11.pdf
    1. Jackson LA, Hilsdon R, Farley MM, Harrison LH, Reingold AL, Plikaytis BD, et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med. 1995;123:415–20. 10.7326/0003-4819-123-6-199509150-00003 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources